HighTide Therapeutics Valuation

Is 2511 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 2511 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 2511's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 2511's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 2511?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for 2511. This is calculated by dividing 2511's market cap by their current preferred multiple.
What is 2511's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	CN¥568.32m

2511 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	-0.07x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does 2511's PB Ratio compare to its peers?

The above table shows the PB ratio for 2511 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	0.6x
2126 JW (Cayman) Therapeutics	0.4x	-1.8%	HK$578.5m
1244 3D Medicines	0.6x	n/a	HK$529.3m
2137 Brii Biosciences	0.3x	-7.4%	HK$789.7m
2898 Sunho Biologics	1.3x	n/a	HK$753.3m
2511 HighTide Therapeutics	1x	n/a	HK$622.9m

Price-To-Book vs Peers: 2511 is expensive based on its Price-To-Book Ratio (1x) compared to the peer average (0.6x).

Price to Earnings Ratio vs Industry

How does 2511's PE Ratio compare vs other companies in the HK Biotechs Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	41.8%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	41.8%
	n/a	n/a	n/a

No more companies

Price-To-Book vs Industry: 2511 is good value based on its Price-To-Book Ratio (1x) compared to the Hong Kong Biotechs industry average (2x).

Price to Book Ratio vs Fair Ratio

What is 2511's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

2511 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	1x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 2511's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.